EscharEx - MediWound

Drug Profile

EscharEx - MediWound

Alternative Names: EscharEx

Latest Information Update: 23 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MediWound
  • Class Enzymes; Skin disorder therapies
  • Mechanism of Action Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Leg ulcer; Wounds

Most Recent Events

  • 16 Nov 2017 MediWound completes enrolment in a phase II trial for Leg ulcer and Wounds in Hungry and Israel
  • 01 Sep 2017 Topline safety data from a phase II trial in Wounds and Leg ulcer released by MediWound
  • 03 Aug 2017 MediWound plans a phase III trial in USA in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top